Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
More News related to GHDX
- Genomic Health to Present at Piper Jaffray Health Care Conference
- Genomic Health (GHDX) Tops Q3 EPS by 7c
- Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
More News related to Upgrades
- Goldman Sachs Upgraded US REITS to Neutral; Ups BKD, AVB, GGWPQ, Downgrades KIM
- Fitch Upgrades Turkey's Sovereign Rating Two Notches to 'BB+'
- Bank of America upgrades Weyerhaeuser (WY) to Buy
- FBR Capital Upgrades Bank of America (BAC) to Outperform After Capital Raise Announcement
- Boenning & Scattergood Downgrades NutriSystem (NTRI) to Neutral
Thomas Weisel upgrades Genomic Health (Nasdaq: GHDX) from Marketweight to Overweight. Price target $23.
To see more analyst ratings on GHDX Click Here.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
